Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.

Publication ,  Journal Article
Lawitz, E; Rodriguez-Torres, M; Muir, AJ; Kieffer, TL; McNair, L; Khunvichai, A; McHutchison, JG
Published in: J Hepatol
August 2008

BACKGROUND/AIMS: This study assessed the safety and antiviral effects of telaprevir (VX-950) in combination with peginterferon alfa-2a and ribavirin. METHODS: Twelve treatment-naïve patients with chronic genotype 1 hepatitis C virus infection received telaprevir (750 mg q8h), peginterferon alfa-2a (180 microg/week), and ribavirin (1000 or 1200 mg/day) for 28 days. Patients could then start off-study treatment with peginterferon alfa-2a and ribavirin for up to 44 weeks, at the discretion of the investigator and patient. RESULTS: The combination of telaprevir, peginterferon alfa-2a, and ribavirin was well tolerated, with no serious adverse events or treatment discontinuations. Rash or pruritus occurred in 5 of the 12 patients; all cases resolved either during or after the end of telaprevir treatment. All 12 patients had undetectable HCV RNA levels by day 28 (rapid viral response, RVR). Eight patients completed 44 weeks of off-study peginterferon alfa-2a and ribavirin treatment. Eight patients achieved a sustained viral response (SVR), including one patient who received only 22 weeks of treatment. CONCLUSIONS: The combination of telaprevir, peginterferon alfa-2a, and ribavirin was generally well tolerated. Events of pruritus and rash resolved during or after end of telaprevir dosing. All 12 patients achieved an RVR.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Hepatol

DOI

ISSN

0168-8278

Publication Date

August 2008

Volume

49

Issue

2

Start / End Page

163 / 169

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Ribavirin
  • Recombinant Proteins
  • RNA, Viral
  • Polyethylene Glycols
  • Oligopeptides
  • Middle Aged
  • Male
  • Interferon-alpha
  • Interferon alpha-2
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lawitz, E., Rodriguez-Torres, M., Muir, A. J., Kieffer, T. L., McNair, L., Khunvichai, A., & McHutchison, J. G. (2008). Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol, 49(2), 163–169. https://doi.org/10.1016/j.jhep.2008.03.027
Lawitz, Eric, Maribel Rodriguez-Torres, Andrew J. Muir, Tara L. Kieffer, Lindsay McNair, Ariya Khunvichai, and John G. McHutchison. “Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.J Hepatol 49, no. 2 (August 2008): 163–69. https://doi.org/10.1016/j.jhep.2008.03.027.
Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008 Aug;49(2):163–9.
Lawitz, Eric, et al. “Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.J Hepatol, vol. 49, no. 2, Aug. 2008, pp. 163–69. Pubmed, doi:10.1016/j.jhep.2008.03.027.
Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol. 2008 Aug;49(2):163–169.
Journal cover image

Published In

J Hepatol

DOI

ISSN

0168-8278

Publication Date

August 2008

Volume

49

Issue

2

Start / End Page

163 / 169

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Ribavirin
  • Recombinant Proteins
  • RNA, Viral
  • Polyethylene Glycols
  • Oligopeptides
  • Middle Aged
  • Male
  • Interferon-alpha
  • Interferon alpha-2